Gold steadies above $ 1240 ahead of Healthcare vote
|Gold prices on Comex failed another attempt to survive again $ 1250 mark and drifted lower in the overnight trades to now waver in a tight range above $ 1240 levels.
Gold hovers near 5-DMA at $1243
Currently, gold trades marginally lower at $ 1243.55, clinging to $ 1242 support. Gold prices rallied to the highest levels since Feb 28 on US data disappointment and uncertainty over the US House vote on the Trumpcare bill, after the vote was postponed to Friday.
However, fresh clarity provided on the timings of the House vote earlier today provided extra legs to the recovery in the US dollar across the board, keeping gold on the back foot. Moreover, persisting risk-on sentiment amid rallying Asian equities and treasury yields also dull the attractiveness of gold as a safe-haven asset.
All eyes now remain on the US durable goods data and Fed official Evans speech due alter today ahead of Trumpcare bill vote.
Comex Gold Technical Levels
The metal has an immediate resistance at 1250 (round number) and 1253.15 (3-week tops). Meanwhile, the support stands at 1240 (zero figure) below which doors could open for 1236.45 (classic S2/ Fib S3).
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.